FDA Brief

Warning letters Drugs

FDA warning letter to

Ready Med

LowIssued Jun 8Posted Jun 16Center for Drug Evaluation and Research (CDER)

FDA warned Ready Med over website claims that compounded semaglutide and tirzepatide products were FDA-approved or FDA-licensed.

What happened

FDA reviewed Ready Med's website, https://readymednow.com, in May 2026 and found it offered compounded semaglutide and tirzepatide products. FDA said the site used labels naming Ready Med or Ready Med Medical Weight Loss Center as if Ready Med were the compounder, compared the products to Mounjaro/Zepbound/Ozempic/Rybelsus by saying they have the same active ingredient, and claimed the products came from an “FDA licensed compounding facility.” FDA said these statements were false or misleading and made the products misbranded.

What FDA found

  1. Website labels pictured Ready Med or Ready Med Medical Weight Loss Center on compounded semaglutide/tirzepatide products, suggesting Ready Med made them when it did not.

    FD&C Act § 502(a) [21 U.S.C. § 352(a)]; 21 C.F.R. § 201.1(h)(2)
  2. Website said compounded semaglutide/tirzepatide have “the same active ingredient” as Mounjaro and Zepbound, implying FDA approval or evaluation when compounded products are not FDA-approved.

    FD&C Act § 502(a), § 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  3. Website said compounded semaglutide/tirzepatide have “the same active ingredient” as Ozempic and Rybelsus, implying FDA approval or evaluation when they have not been FDA-approved.

    FD&C Act § 502(a), § 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  4. Website claimed products came from an “FDA licensed compounding facility,” but FDA does not license or approve compounding pharmacies or outsourcing facilities or their compounded products.

    FD&C Act § 502(a), § 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
  5. FDA said introducing these misbranded products into interstate commerce is a prohibited act.

    FD&C Act § 301(a) [21 U.S.C. § 331(a)]

What FDA wants

FDA asks Ready Med to respond in writing within 15 business days with corrective steps and documentation, including identifying the entities that produce the compounded products, providing sample labeling, and correcting or removing the misleading website claims. It also asks the company to investigate root causes and prevent recurrence.

Who should pay attention

  • telehealth weight-loss platforms selling compounded semaglutide or tirzepatide
  • compounding pharmacies and outsourcing facilities whose products are marketed by clinics
  • online drug sellers using FDA-approved or FDA-licensed language

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low